| Abstract: | PHARMACEUTICAL COMPOSITIONS COMPRISING A PHARMACEUTICAL CARRIER TOGETHER WITH A BIS-CHROMONYL COMPOUND SELECTED FROM COMPOUNDS OF THE FORMULA ((2-(HOOC-),4-(O=),R1,R2,R3-4H-CHROMENYL)-O-X-O-),4-(O=), 2-(HOOC-),R4,R5,R6-4H-CHROMENE AND FUNCTIONAL DERIVATIVES THEREOF, IN WHICH R1, R2, R3, R4, R5 AND R6 ARE EACH SELECTED FROM THE GROUP CONSISTING OF HYDROGEN, HALOGEN, HYDROXY, LOWER ALKYL, LOWER ALKOXY, HYDROXYLOWERALKYL, HALOLOWERALKYL, HYDROXYLOERALKOXY, LOWERALOXYLOWERALKOXY AND CARBOXYLOWERALKOXY; AND X IS SLECTED FROM THE GROUP CONSISTING OF SATURATED AND UNSTURATED, STRAIGHT AND BRANCHES HYDROCARBON CHAINS WHICH MAY BE INTERRUPTED BY AT LEAST ONE MEMBER SELECTED FROM THE GROUP CONSISTING OF BENZENE RINGS, OXYGENCONTAINING HETEROCYLIC RINGS, OXYGEN ATOMS AND CARBONYL GROUPS, AND WHICH MAY BE SUBSTITUTED BY AT LEAST ONE MEMBER, SELECTED FROM THE GROUP CONSISTING OF HALOGEN ATOMS, HYDROXY GROUPS AND LOWER ALOXY GROUPS, ARE USEFUL IN INHIBITING ANTIGEN-ANTIBODY REACTIONS. |
|
Patent landscape, scope, and claims: |
US Patent 3,777,033: What Scope Do the Claims Cover and How Does It Shape the Patent Landscape?
What is US Patent 3,777,033 and when did it issue?
US Patent 3,777,033 issued Dec. 4, 1973. It is a drug patent in the US system, but the provided prompt contains only the statement “The claims are:” and does not include the actual claim text.
No further claim-by-claim scope analysis can be produced without the claims themselves (independent and dependent claim language). Patent scope and landscape outcomes depend on claim elements, defined terms, and claim construction anchors (formulations, dosage regimens, chemical structures, and manufacturing limitations).
No claim set was included in the input, so a complete and accurate analysis cannot be generated under the operating constraints.
What does the claim set say?
The prompt does not provide the claim text. As a result, the following items cannot be accurately determined for US 3,777,033:
- Independent claim boundaries (core inventions vs. surrounding embodiments)
- Claim elements and limitations (chemical structure, salt forms, excipients, process steps, route of administration)
- Doctrinal leverage (means-plus-function triggers, product-by-process, Markush groups, dependence structure)
- Claim interpretation impact (criticality of specific substitutions, ranges, or parameter thresholds)
- FTO-style mapping (which generic or follow-on products would likely fall in/out)
How would the patent landscape be assessed (based on scope)?
A proper landscape requires claim-driven filters such as:
- Same drug substance vs. new salt/ester vs. new polymorph
- Same dosage form vs. new formulation (release profile, bioavailability enhancer, tablet/gelatin capsule format)
- Same method of treatment vs. new indication
- Same manufacturing route vs. new synthetic intermediate or process condition
- Same active-plus-excipient combination vs. one-component substitution
Without claim text, any landscape analysis would be speculative, and the operating constraints bar that.
Key Takeaways
- US Patent 3,777,033 issued Dec. 4, 1973, but the provided prompt does not include the claim text, so scope and landscape analysis cannot be completed accurately.
- Claim wording is the controlling input for determining what is protected and how later patents and generic entries are likely to interact.
- A claim-level review requires the full independent and dependent claims to map coverage and assess design-around space.
FAQs
-
Can I analyze claim scope without the actual claim text?
No. Scope analysis depends on the specific limitations and how dependent claims add restrictions.
-
What does “patent landscape” mean in this context?
It means identifying later patents and potential generic entry risk areas that overlap with the protected subject matter defined in the claims.
-
What matters most for coverage of a drug patent?
Typically the independent claim elements: the active ingredient form, dosage form, formulation constraints, and any treatment or process limitations.
-
How do you identify design-around opportunities?
By reading claim elements and determining which features are essential vs. optional under dependence and claim construction.
-
Do issuance date and patent number alone determine scope?
No. Scope is determined by claim language, with the specification and prosecution history affecting interpretation.
References
- US Patent 3,777,033. (Issued Dec. 4, 1973). (Source not provided in the prompt.)
More… ↓
⤷ Start Trial
|
